Scarica l'app Stockscreener
28.46
0.07%
0.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RARE Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$28.44
Aprire:
$28.68
Volume 24 ore:
1.65M
Relative Volume:
0.96
Capitalizzazione di mercato:
$2.69B
Reddito:
$522.75M
Utile/perdita netta:
$-558.99M
Rapporto P/E:
-4.3988
EPS:
-6.47
Flusso di cassa netto:
$-439.53M
1 W Prestazione:
+3.08%
1M Prestazione:
-28.69%
6M Prestazione:
-35.58%
1 anno Prestazione:
-43.61%
Intervallo 1D:
$27.88
$28.80
Intervallo di 1 settimana:
$26.85
$28.80
Portata 52W:
$25.81
$60.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Nome
Ultragenyx Pharmaceutical Inc
Settore
Industria
Telefono
415-483-8800
Indirizzo
60 LEVERONI COURT, NOVATO, CA
Confronta RARE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
28.46 | 2.69B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 118.67B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.54 | 59.23B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
419.56 | 52.67B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
690.32 | 41.24B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
304.30 | 32.36B | 3.81B | -644.79M | -669.77M | -6.24 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-28 | Ripresa | H.C. Wainwright | Buy |
| 2025-05-28 | Iniziato | William Blair | Outperform |
| 2024-06-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-04-22 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-06-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Ripresa | Canaccord Genuity | Buy |
| 2022-12-30 | Ripresa | H.C. Wainwright | Buy |
| 2022-11-03 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-08-01 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-08-19 | Iniziato | UBS | Sell |
| 2021-07-15 | Iniziato | Guggenheim | Neutral |
| 2021-06-29 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-05-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-05-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-02 | Ripresa | Stifel | Buy |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2020-11-24 | Ripresa | Evercore ISI | In-line |
| 2020-11-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2019-08-02 | Ripresa | Wedbush | Outperform |
| 2019-03-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Aggiornamento | Citigroup | Sell → Neutral |
| 2018-09-10 | Iniziato | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Iniziato | Goldman | Neutral |
| 2018-04-18 | Aggiornamento | SunTrust | Hold → Buy |
| 2018-03-22 | Ripresa | Piper Jaffray | Overweight |
| 2018-02-21 | Reiterato | Stifel | Buy |
| 2018-01-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Iniziato | Credit Suisse | Outperform |
| 2017-12-05 | Reiterato | Barclays | Equal Weight |
| 2017-12-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2017-09-14 | Aggiornamento | Wedbush | Neutral → Outperform |
Mostra tutto
Ultragenyx Pharmaceutical Inc Borsa (RARE) Ultime notizie
Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory - Insider Monkey
What to Expect From Ultragenyx Pharmaceutical's Earnings - 富途牛牛
Ultragenyx Pharmaceutical Inc. stock momentum explainedTechnical Setup Guide for Daily Watchlist - Newser
Published on: 2025-08-04 05:51:46 - Newser
Is Ultragenyx Pharmaceutical Inc. a growth stock or a value stockExceptional trading results - Jammu Links News
Is Ultragenyx Pharmaceutical Inc. stock overvalued or undervaluedRecord-setting profit potential - Jammu Links News
How volatile is Ultragenyx Pharmaceutical Inc. stock compared to the marketMarket-leading growth rates - Jammu Links News
New Product Launches: Will They Boost Ultragenyx Pharmaceutical Inc. Stock in 2025Free Low Drawdown Real Time Trading Tips - Newser
What catalysts could drive Ultragenyx Pharmaceutical Inc. stock higher in 2025Maximize gains with expert analysis - Jammu Links News
What are the technical indicators suggesting about Ultragenyx Pharmaceutical Inc.Invest confidently with professional market insights - Jammu Links News
What are the latest earnings results for Ultragenyx Pharmaceutical Inc.Explosive returns - Jammu Links News
What institutional investors are buying Ultragenyx Pharmaceutical Inc. stockGet daily updates on promising stocks - Jammu Links News
How strong is Ultragenyx Pharmaceutical Inc. company’s balance sheetUnlock exclusive stock market insights - Jammu Links News
Ultragenyx Pharmaceutical Inc. Stock Analysis and ForecastCapitalize on emerging investment opportunities - Jammu Links News
Why is Ultragenyx Pharmaceutical Inc. stock attracting strong analyst attentionRapid-fire capital growth - Jammu Links News
What is the dividend policy of Ultragenyx Pharmaceutical Inc. stockFree Stock Market Trend Analysis - Jammu Links News
Ultragenyx to Report Q2 2025 Financial Results and Host Corporate Update Conference Call on August 5, 2025. - AInvest
Price action breakdown for Ultragenyx Pharmaceutical Inc.Free Buy Alerts With Low Risk Confirmation - Newser
How hedge fund analytics apply to Ultragenyx Pharmaceutical Inc. stockSummary of Trade Cycles in 5-Year Range - Newser
What makes Ultragenyx Pharmaceutical Inc. stock price move sharplyFree Risk Controlled Picks With Real Returns - Newser
Ultragenyx Pharmaceutical Inc expected to post a loss of $1.30 a shareEarnings Preview - TradingView
Ultragenyx Completes Enrollment for GTX-102 Phase 3 Study - The Globe and Mail
Pomerantz LLP investigating Ultragenyx Pharmaceutical for potential securities fraud. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - GlobeNewswire Inc.
Ultragenyx completes enrollment for phase 3 Angelman syndrome study By Investing.com - Investing.com Australia
Ultragenyx completes enrollment for phase 3 Angelman syndrome study - Investing.com
How Ultragenyx Pharmaceutical Inc. stock performs during market volatilityHigh Conviction Screener with Trend Matching - Newser
Ultragenyx Completes Enrollment of Phase 3 Aspire Study - GlobeNewswire
Breakthrough Angelman Syndrome Drug Trial Hits Major Milestone: 129 Patients Enrolled in Record Time - Stock Titan
Ultragenyx Pharmaceutical Inc. (RARE) Receives FDA CRL for UX111, Plans Quick Resubmission - AInvest
Ultragenyx Pharmaceutical Inc. (RARE) Gets FDA CRL for UX111, Vows Quick Resubmission - Insider Monkey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - PR Newswire
Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update - GlobeNewswire
Why Ultragenyx Pharmaceutical Inc. stock attracts strong analyst attentionSummary of Reliable Long-Term Trade Models - Newser
Ultragenyx Pharmaceutical Inc. stock trendline breakdownHigh Return Trade Roadmap with Setup Filters - Newser
Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Ultragenyx Pharmaceutical to Host Q2 2025 Financial Results Conference Call on August 5, 2025. - AInvest
Ultragenyx's Strategic Momentum: Catalyzing Long-Term Value Through Revenue Growth and Gene Therapy Innovation - AInvest
Ultragenyx Pharmaceutical Inc. to Host Conference Call for Q2 2025 Financial Results and Corporate Update - Quiver Quantitative
Rare Disease Leader Ultragenyx Sets Q2 2025 Earnings Call: Key Updates Expected for Genetic Disease Pipeline - Stock Titan
Ultragenyx Bets On Rare Diseases Despite Rocky Results - Finimize
Ultragenyx Pharmaceutical Inc. Shows Early Signs of Technical Strength - metal.it
Ultragenyx: July Selloff Creates Buying Opportunity Ahead Of UX143 Catalyst (NASDAQ:RARE) - Seeking Alpha
Visual trend scoring systems applied to Ultragenyx Pharmaceutical Inc.Swing Trade Entry and Exit Point Analysis - Newser
Ultragenyx Pharmaceutical Inc Azioni (RARE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):